BioTuesdays

Author - Leonard Zehr

Feature

Mateon taking VDAs in new direction against cancer

By Len Zehr Mateon Therapeutics (NASDAQ:MATN) is developing vascular disrupting agents (VDAs) that selectively disrupt abnormal tumor blood vessels, which supply nutrients to cancer cells, with an initial clinical focus...

September 13, 2016
Dipexium Pharmaceuticals
Developments

Dipexium receives Locilex patent in EU

Dipexium Pharmaceuticals (NASDAQ:DPRX) said that the European Patent Office has issued a new Locilex patent in the EU. The patent claims are directed to a novel formulation of Locilex, a topical antimicrobial peptide...

September 7, 2016
ASLAN Pharmaceuticals
Developments

ASLAN Pharma in licensing pact with A*STAR

Closely-held ASLAN Pharmaceuticals has licensed a novel immuno-oncology antibody, targeting RON (Recepteur d’Origine Nantais), from Singapore’s Agency for Science, Technology and Research (A*STAR). RON is a receptor...

September 1, 2016
Valeant Pharmaceuticals
Developments

Valeant to commercialize Contrave in Canada

Valeant Canada, a subsidiary of Valeant Pharmaceuticals International (NYSE, TSX: VRX), will commercialize Orexigen Therapeutics’ (NASDAQ:OREX) Contrave (naltrexone HCl / bupropion HCl extended release) in Canada. Under...

August 30, 2016
Feature

BioSyent to target international markets

By Len Zehr BioSyent (OTC:BIOYF; TSX-V:RX) is actively building its international pharmaceutical sales and marketing business, adding products licensed and sold internationally to products already being shipped from...

August 30, 2016
Neuralstem
Markets

Roth starts Neuralstem at buy

Roth Capital Partners launched coverage of Neuralstem (NASDAQ:CUR) with a “buy” rating and price target of $1.20. The stock closed at 25 cents on Friday. Analyst Joseph Pantginis writes that Neuralstem has undergone a...

August 29, 2016
Actinium
Markets

Roth starts Actinium Pharma at buy

Roth Capital Partners initiated coverage of Actinium Pharmaceuticals (NYSE MKT:ATNM) with a “buy” rating and $5 price target. The stock closed at $1.66 on Wednesday. “We believe it is an opportune time to explore the...

August 25, 2016